DekaBank Deutsche Girozentrale Raises Stock Holdings in Zoetis Inc (NYSE:ZTS)

Share on StockTwits

DekaBank Deutsche Girozentrale increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 17.5% in the second quarter, HoldingsChannel reports. The firm owned 502,972 shares of the company’s stock after buying an additional 74,854 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zoetis were worth $56,892,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in shares of Zoetis by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after acquiring an additional 39,319 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after acquiring an additional 785,088 shares in the last quarter. CAPROCK Group Inc. purchased a new position in shares of Zoetis in the first quarter valued at approximately $209,000. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in shares of Zoetis in the first quarter valued at approximately $25,000. Finally, Retirement Systems of Alabama lifted its position in shares of Zoetis by 0.3% in the first quarter. Retirement Systems of Alabama now owns 222,938 shares of the company’s stock valued at $22,443,000 after acquiring an additional 741 shares in the last quarter. Hedge funds and other institutional investors own 90.08% of the company’s stock.

Several equities research analysts have issued reports on the company. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Stifel Nicolaus raised their target price on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Barclays raised their target price on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Finally, Guggenheim assumed coverage on Zoetis in a research note on Thursday, May 23rd. They set a “buy” rating and a $114.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $115.13.

In related news, CFO Glenn David sold 8,191 shares of Zoetis stock in a transaction on Friday, May 17th. The stock was sold at an average price of $102.22, for a total value of $837,284.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,900 shares of Zoetis stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total value of $210,102.00. Following the completion of the transaction, the director now owns 2,816 shares of the company’s stock, valued at $311,393.28. The disclosure for this sale can be found here. Insiders sold 29,537 shares of company stock valued at $3,184,955 over the last ninety days. Insiders own 0.29% of the company’s stock.

Shares of NYSE ZTS opened at $124.70 on Wednesday. Zoetis Inc has a twelve month low of $78.90 and a twelve month high of $125.88. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. The company has a fifty day moving average price of $115.93. The firm has a market capitalization of $59.87 billion, a PE ratio of 39.84, a PEG ratio of 3.16 and a beta of 0.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the previous year, the firm posted $0.77 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. As a group, analysts expect that Zoetis Inc will post 3.57 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be paid a $0.164 dividend. The ex-dividend date is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.53%. Zoetis’s payout ratio is presently 21.09%.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: How to find the components of the quick ratio

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Assetmark Inc. Has $17.21 Million Stake in VANGUARD SCOTTS/VANGUARD SHORT-TERM
Assetmark Inc. Has $17.21 Million Stake in VANGUARD SCOTTS/VANGUARD SHORT-TERM
Northland Securities Reaffirms Hold Rating for Palo Alto Networks
Northland Securities Reaffirms Hold Rating for Palo Alto Networks
Comparing Elanco Animal Health  and Its Competitors
Comparing Elanco Animal Health and Its Competitors
AAC TECHNOLOGIE/ADR  and Magal Security Systems  Head to Head Review
AAC TECHNOLOGIE/ADR and Magal Security Systems Head to Head Review
Contrasting UDR  and National Health Investors
Contrasting UDR and National Health Investors
Reviewing Corelogic  & RingCentral
Reviewing Corelogic & RingCentral


© 2006-2019 Ticker Report